Group A Meningococcal disease is a significant cause of morbidity and mortality world-wide. Epidemic disease continues to develop regularly in the meningitis belt of Africa and recent epidemics have also occurred in New Zealand and Saudi Arabia . In the U.S., meningococcal polysaccharide vaccine is administered to all military recruits and patients with functional or anatomic asplenia. Recent studies involving investigational Group A polysaccharide-protein conjugate vaccines have unexpectedly shown lack of B cell memory. Children receiving primary immunizations with protein conjugated group A polysaccharide did not show a booster response when subsequently vaccinated with native polysaccharide. This is in contrast to similar studies using Haemophilus influenzea group B (HIB) conjugate vaccines followed by HIB polysaccharide, or Meningococcal group C conjugate vaccines followed by native group C meningococcal polysaccharide. Our initial studies are focused on assessing the immunological importance of the O-acetyl groups of the native Group A meningococcal polysaccharide. Group A polysaccharide was de-O-acetylated using alkaline hydrolysis. ELISA inhibition assays showed that antibodies raised in response to immunization with the native group A polysaccharide are not inhibited as well by de-O-acetylated polysaccharide as they are by native polysaccharide suggesting the O-acetyl groups of group A meningococcal polysaccharide are immunologically important. Immunization of mice with OAc+ and OAC- Group A PS protein conjugate vaccines and OAc+ and OAc- PS vaccines have been completed. Analysis of the immune responses with ELISA and ELISA inhibition assays also suggests the OAc groups of meningococcal group A PS contribute to important antigenic epitopes of the PS. Bacteridial assays revealed high titer bactericidal activity in sera from mice immunized with OAc+ Group A PS conjugate vaccine and native OAc+ PS, but not in those immunized with OAc- conjugate or PS vaccine. The immunization studies have been repeated and confirmed our original findings.

Agency
National Institute of Health (NIH)
Institute
Center for Biologics Evaluation and Research - Bactrial Products (CBERBP)
Type
Intramural Research (Z01)
Project #
1Z01BJ002026-04
Application #
6433467
Study Section
Large Bowel and Pancreatic Cancer Review Committee (LBP)
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
2000
Total Cost
Indirect Cost